
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant

Filed by a party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

Orogenics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No Fee Required

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



Your **Vote** Counts!

ORAGENICS, INC.
2023 Annual Meeting
Vote by December 13, 2023
11:59 PM ET



Hexstone, Inc.
P.O. Box 9142
Farmingdale, NY 11735

Ricky Campana
P.O. Box 123456
Suite 500
51 Mercedes Way
Edgewood, NY 11717

1 OF 2
322,224
148,294

30#



FLASHID-JOB#

You invested in ORAGENICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on December 14, 2023.**

Get informed before you vote

View the 10K Wrap, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to November 30, 2023. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

For complete information and to vote, visit www.ProxyVote.com

Control #



Smartphone users
Point your camera here and vote without entering a control number



Vote by Mail
Submit with your prepaid envelope



Vote by Phone
800-690-6903



Vote in Person at the Meeting*
December 14, 2023
9:00 AM EST
101 E Kennedy Blvd
Suite 2800
Tampa, FL 33602

*If you choose to vote these shares in person at the meeting, you must request a "legal proxy." To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the Annual Meeting. Complete proxy materials are available on the Internet or by mail. We encourage shareholders to review all proxy materials prior to voting.

ORAGENICS, INC.
2023 Annual Meeting
Vote by December 13, 2023
11:59 PM ET

You may access the materials for the Annual Meeting by visiting:
<https://www.cstproxy.com/oragenics/2023>

Check this box if you plan to attend the meeting and vote your shares. To ensure entry, you should review the meeting attendance requirements in the proxy statement.

Voting Items		Board Recommendations	Voting Options		
1.	Election of Directors Nominees:		For	Withhold	
1A	Charles L. Pope	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	
1B	Robert C. Koski	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	
1C	Frederick W. Telling	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	
1D	Dr. Alan W. Dunton	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	
1E	Kimberly M. Murphy	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	
1F	John P. Gandolfo	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	
1G	Bruce Cassidy	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	
2.	ADVISORY VOTE ON EXECUTIVE COMPENSATION.	☑ For	For	Against	Abstain
3.	APPROVAL OF THE ADOPTION OF AN AMENDMENT TO COMPANY'S ARTICLES OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 4,166,666 SHARES TO 350,000,000 SHARES.	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4.	APPROVAL OF THE ADJOURNMENT OF THE ANNUAL MEETING IN THE EVENT THAT THE NUMBER OF SHARES OF COMMON STOCK AND SERIES E MIRRORING PREFERRED STOCK PRESENT OR REPRESENTED BY PROXY AT THE ANNUAL MEETING AND VOTING FOR THE ADOPTION OF PROPOSAL 3 ARE INSUFFICIENT.	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.	TO APPROVE, IN ACCORDANCE WITH NYSE AMERICAN COMPANY GUIDE SECTION 712(B), THE ISSUANCE OF THE COMMON STOCK UPON CONVERSION OF THE COMPANY'S SERIES F PREFERRED STOCK, WHICH SHARES OF SERIES F CONVERTIBLE STOCK ARE ISSUABLE UPON THE CLOSING OF THE ASSET PURCHASE AGREEMENT BETWEEN THE COMPANY AND ODYSSEY HEALTH, INC. F/K/A ODYSSEY GROUP INTERNATIONAL, INC., A NEVADA CORPORATION, DATED OCTOBER 4, 2023.	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.	APPROVAL OF AN AMENDMENT TO THE COMPANY'S 2021 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF COMMON SHARES AVAILABLE FOR ISSUANCE UNDER THE 2021 EQUITY INCENTIVE PLAN FROM 166,667 SHARES OF COMMON STOCK TO 1,166,667 SHARES OF COMMON STOCK.	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.	RATIFICATION OF THE SELECTION OF CHERRY BEKAERT LLP AS THE COMPANY'S INDEPENDENT AUDITORS FOR THE YEAR ENDING DECEMBER 31, 2023.	☑ For	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
NOTE: Such other business as may properly come before the meeting or any adjournment thereof.					

Under New York Stock Exchange rules, brokers may vote "routine" matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. **We will nevertheless follow your instructions, even if the broker's discretionary vote has already been given, provided your instructions are received prior to the meeting date.**

Signature

Date

FLASHID-JOB#

1.00000
322,224
148,294